

DAFTAR PUSTAKA

Agistia, N., Mukhtar, H. and Nasif, H. (2017) 'Efektifitas Antibiotik pada Pasien Ulkus Kaki Diabetik', *Jurnal Sains Farmasi & Klinis*, 4(1), pp. 43–48. doi: 10.29208/jsfk.2017.4.1.144.

Anggowarsito, J. L. (2014) 'Aspek Fisiologi Penuaan Kulit', *Widiya Medika Surabaya*, 2(1), pp. 56–61. Available at: <http://journal.wima.ac.id/index.php/JWM/article/view/1652>.

Cárdenas, M. K. *et al.* (2015) 'The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru', *BMC Health Services Research*, 15(1), pp. 1–11. doi: 10.1186/s12913-015-1141-4.

Casqueiro, Juliana, Casqueiro, Janine and Alves, C. (2012) 'Infections in patients with diabetes mellitus: A review of pathogenesis', *Indian Journal of Endocrinology and Metabolism*, 16(7), p. 27. doi: 10.4103/2230-8210.94253.

Cheng, Q. *et al.* (2017) 'A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia', *International Wound Journal*, 14(4), pp. 616–628. doi: 10.1111/iwj.12653.

Chodijah, S., Nugroho, A. and Pandelaki, K. (2013) 'Hubungan Kadar Gula Darah Puasa Dengan Jumlah Leukosit Pada Pasien Diabetes Mellitus Dengan Sepsis', *Jurnal e-Biomedik*, 1(1). doi: 10.35790/ebm.1.1.2013.4606.

Copenhaver, M. and Hoffman, R. P. (2017) 'Type 1 diabetes: Where are we in 2017?', *Translational Pediatrics*, 6(4), pp. 359–364. doi: 10.21037/TP.2017.09.09.

Hadning, I., Ikawati, Z. and Andayani, T. M. (2015) 'Stroke Treatment Cost Analysis for Consideration on Health Cost Determination Using INA- CBGs at Jogja Hospital', *International Journal of Public Health Science*, 4(4). Available

at: <http://ijphs.iaescore.com/index.php/IJPHS/article/view/4748>.

Harreiter, J. and Kautzky-Willer, A. (2018) 'Sex and Gender Differences in Prevention of Type 2 Diabetes', *Frontiers in Endocrinology*, 9, pp. 1–15. doi: 10.3389/fendo.2018.00220.

Hasnah, S., Septiani and Dewi, A. P. (2021) 'ANALISIS JUMLAH LEUKOSIT PADA PENDERITA ULKUS DIABETIKUM DIABETES MELLITUS TIPE 2', 2(3).

Hopkins, R. B. *et al.* (2015) 'Economic burden of illness associated with diabetic foot ulcers in Canada'. doi: 10.1186/s12913-015-0687-5.

Hutagalung, M. B. Z. *et al.* (2019) 'Diabetic Foot Infection (Infeksi Kaki Diabetik): Diagnosis dan Tatalaksana', *Continuing Medical Education*, 46(6), pp. 414–418.

Ibrahim, A. *et al.* (2017) *IDF Clinical Practice Recommendations on the Diabetic Foot – 2017, International Diabetes Federation*. doi: 10.1016/j.diabres.2017.09.002.

Imran, S. A. *et al.* (2018) 'Targets for Glycemic Control', *Canadian Journal of Diabetes*, 42, pp. S42–S46. doi: 10.1016/j.jcjd.2017.10.030.

Isnaini, N. and Ratnasari (2018) 'Faktor Risiko Mempengaruhi Kejadian Diabetes mellitus Tipe Dua', *Jurnal Kebidanan dan Keperawatan Aisyiyah*, 14(1), pp. 59–68. doi: 10.31101/jkk.550.

Kartika, R. W. (2017) 'Pengelolaan gangren kaki Diabetik', *Cermin Dunia Kedokteran*, 44(1), pp. 18–22.

KEMENKES RI (2013) *PEDOMAN PENERAPAN KAJIAN FARMAKOEKONOMI*.

Kementrian Kesehatan RI (2020) *Tetap Produktif, Cegah, dan Atasi Diabetes Melitus 2020, Pusat Data dan Informasi Kementrian Kesehatan RI*. Available at: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/Infodatin->

2020-Diabetes-Melitus.pdf.

Khoiriyah, S. D. and Lestari, K. (2019) 'REVIEW ARTIKEL: KAJIAN FARMAKOEKONOMI YANG MENDASARI PEMILIHAN PENGOBATAN DI INDONESIA', *Farmaka*, 16(3), pp. 134–145. doi: 10.24123/mpi.v2i2.1391.

Lipsky, B. A. *et al.* (2019) 'IWGDF Guideline on the diagnosis and treatment of foot infection in persons with diabetes', *IWGDF Guidelines*, pp. 1–43. Available at: www.iwgdfguidelines.org.

Lubis, I. K. and Susilawati, S. (2018) 'Analisis Length Of Stay (Los) Berdasarkan Faktor Prediktor Pada Pasien DM Tipe II di RS PKU Muhammadiyah Yogyakarta', *Jurnal Kesehatan Vokasional*, 2(2), p. 161. doi: 10.22146/jkesvo.30330.

Maryunani, A. (2015) *Perawatan luka modern (modern woundcare) terkini dan terlengkap*. In Media.

Muennig, P. and Bounthavong, M. (2016) *Cost-Effectiveness Analysis in Health: A Practical Approach*. Available at: [https://books.google.co.id/books?hl=id&lr=&id=P14BCgAAQBAJ&oi=fnd&pg=PP9&dq=cost+effectiveness+analysis&ots=ml7JJYQMsa&sig=Bl6Xi6a4-BtpSewWIBFP4ddBSmE&redir_esc=y#v=onepage&q=cost effectiveness analysis&f=false](https://books.google.co.id/books?hl=id&lr=&id=P14BCgAAQBAJ&oi=fnd&pg=PP9&dq=cost+effectiveness+analysis&ots=ml7JJYQMsa&sig=Bl6Xi6a4-BtpSewWIBFP4ddBSmE&redir_esc=y#v=onepage&q=cost%20effectiveness%20analysis&f=false).

OECD (2017) "'Average Length of Stay in Hospitals", in *Health at a Glance 2017*, *OECD Publishing, Paris*, pp. 176–178. Available at: <http://dx.doi.org/10.1787/>.

Oktorina, R., Wahyuni, A. and Harahap, E. Y. (2019) 'Faktor-Faktor Yang Berhubungan Dengan Perilaku Pencegahan Ulkus Diabetikum Pada Penderita Diabetes Mellitus', *Real in Nursing Journal*, 2(3), pp. 108–117. doi: 10.32883/rnj.v2i3.570.

PERKENI (2015) *Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2015*, *PERKENI*. Available at:

<https://www.google.com/url?sa=t&source=web&rct=j&url=https://pbperkeni.or.id/wp-content/uploads/2019/01/4.-Konsensus-Pengelolaan-dan-Pencegahan-Diabetes-melitus-tipe-2-di-Indonesia-PERKENI-2015.pdf&ved=2ahUKEwjy8KOs8cfoAhXCb30KHQb1Ck0QFjADegQIBhAB&usg=AOv>.

Perpres (2018) ‘Perpres RI No 82 Tahun 2018 Tentang Jaminan Kesehatan’, p. 74.

Prasetyoningtyas, N. W., Sari, E. P. and Shofiyah, S. (2018) ‘Gambaran Jumlah Leukosit Pada Penderita Diabetes Melitus Tipe 2 Yang Tidak Terkontrol’, *Doctoral disertation*, 2(1), pp. 1–5.

Sari, Y. (2015) *Perawatan Luka Diabetes*. Graha Ilmu.

Sari, Y. O., Almasdy, D. and Fatimah, A. (2018) ‘Evaluasi Penggunaan Antibiotik Pada Pasien Ulkus Diabetikum di Instalasi Rawat Inap (IRNA) Penyakit Dalam RSUP Dr. M. Djamil Padang’, *Jurnal Sains Farmasi & Klinis*, 5(2), pp. 102–111. doi: 10.25077/jsfk.5.2.102-111.2018.

Scharper, N. C. *et al.* (2019) ‘IWGDF Guidelines on the Prevention and Management of Diabetic Foot Disease’, *IWGDF Guidelines*, p. 144. doi: 10.33235/wpr.27.3.144.

Suba, Z. (2013) ‘Low Estrogen Exposure and/or Defective Estrogen Signaling Induces Disturbances in Glucose Uptake and Energy Expenditure’, *Journal of Diabetes & Metabolism*, 04(05). doi: 10.4172/2155-6156.1000272.

Tjandrawinata, R. R. (2016) ‘Peran Farmaekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan’, *Working Paper of Dexa Medica Group*, 29(1), pp. 46–52.

da Trindade, M. T. and Salgado, H. R. N. (2018) ‘A Critical Review of Analytical Methods for Determination of Ceftriaxone Sodium’, *Critical Reviews in Analytical Chemistry*, 48(2), pp. 95–101. doi: 10.1080/10408347.2017.1398063.

Widodo, F. . (2017) ‘Monitoring of Patient With Diabetes Mellitus’, *Jurnal*

Ilmiah Kedokteran Wijaya Kusuma, 3(2), p. 55. doi: 10.30742/jikw.v3i2.23.

Woods, T. J. *et al.* (2020) 'Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review', *PLoS ONE*, 15(4), pp. 1–17. doi: 10.1371/journal.pone.0232395.